Markets:

Overview

News

Currencies

International

Treasuries

Medpace Holdings, Inc. - Common Stock (NQ:MEDP)

625.21 +7.17 (+1.16%)

Streaming Delayed Price Updated: 11:11 AM EST, Jan 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Medpace Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Medpace (MEDP): Buy, Sell, or Hold Post Q3 Earnings?

January 15, 2026

What a time it’s been for Medpace. In the past six months alone, the company’s stock price has increased by a massive 96.1%, reaching $617.27 per share. This was partly due to its solid quarterly...

Via StockStory

Topics Supply Chain

2 Healthcare Stocks to Keep an Eye On and 1 We Ignore

January 12, 2026

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only...

Via StockStory

Topics Stocks

1 Mid-Cap Stock with Competitive Advantages and 2 We Avoid

January 04, 2026

Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract...

Via StockStory

December 31, 2025

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other...

Via StockStory

2 Profitable Stocks to Keep an Eye On and 1 We Find Risky

December 11, 2025

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my...

Via StockStory

1 Volatile Stock to Target This Week and 2 We Turn Down

December 07, 2025

Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions. While many thrive during risk-on environments, many also struggle to maintain investor...

Via StockStory

Q3 Rundown: Azenta (NASDAQ:AZTA) Vs Other Drug Development Inputs & Services Stocks

November 27, 2025

As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the drug development inputs & services industry, including Azenta (NASDAQ:AZTA) and its peers.

Via StockStory

Medpace (MEDP) Q3 2025 Earnings Call Transcript ↗

November 27, 2025

Medpace (MEDP) Q3 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Medpace (NASDAQ:MEDP): Strongest Q3 Results from the Drug Development Inputs & Services Group

November 24, 2025

As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the drug development inputs & services industry, including Medpace (NASDAQ:MEDP) and its peers.

Via StockStory

BrightSpring Health Services, 10x Genomics, QuidelOrtho, Medpace, and Fortrea Shares Are Soaring, What You Need To Know

November 24, 2025

A number of stocks jumped in the afternoon session after reports revealed the Trump administration considered extending the Affordable Care Act (ACA) subsidies. These subsidies, which are government...

Via StockStory

Topics Economy Government

MEDPACE HOLDINGS INC (NASDAQ:MEDP) Shows Strong Growth and Momentum Alignment ↗

November 21, 2025

MEDP stock shows strong technical momentum and accelerating earnings growth, fitting a proven strategy for finding leading growth stocks.

Via Chartmill

6 Healthcare Stocks With Strong Upward Momentum ↗

November 18, 2025

Via Benzinga

2 Mooning Stocks to Research Further and 1 We Question

November 11, 2025

The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, positive market sentiment, or significant...

Via StockStory

Topics Economy

Drug Development Inputs & Services Stocks Q3 Results: Benchmarking UFP Technologies (NASDAQ:UFPT)

November 11, 2025

As the Q3 earnings season wraps, let’s dig into this quarter’s best and worst performers in the drug development inputs & services industry, including UFP Technologies (NASDAQ:UFPT) and its peers.

Via StockStory

Q3 Earnings Highs And Lows: IQVIA (NYSE:IQV) Vs The Rest Of The Drug Development Inputs & Services Stocks

November 06, 2025

As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services industry, including IQVIA (NYSE:IQV) and its...

Via StockStory

Drug Development Inputs & Services Stocks Q3 Recap: Benchmarking Repligen (NASDAQ:RGEN)

November 06, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at Repligen (NASDAQ:RGEN) and its peers.

Via StockStory

1 Mid-Cap Stock to Target This Week and 2 We Ignore

November 02, 2025

Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. However, they face intense competition from...

Via StockStory

3 Cash-Heavy Stocks Worth Your Attention

October 30, 2025

In a world where many businesses have shaky balance sheets, some have ignored the crowd and exercised prudence. These cash-heavy companies shine bright for their financial discipline, resilience, and...

Via StockStory

5 Revealing Analyst Questions From Medpace’s Q3 Earnings Call

October 29, 2025

Medpace’s third quarter results were well received by the market, driven by broad-based revenue growth and robust net new business awards. Management credited strong demand across therapeutic...

Via StockStory

Topics Earnings

8 Analysts Assess Medpace Hldgs: What You Need To Know ↗

October 24, 2025

Via Benzinga

Medpace Soars: AI and Data Analytics Propel Clinical Trial Giant to Record Heights

October 24, 2025

Medpace Holdings, Inc. (NASDAQ: MEDP), a leading global contract research organization (CRO), has been experiencing an unprecedented surge in its stock value, reaching an all-time high of $543.90 on...

Via TokenRing AI

Topics Artificial Intelligence

Why Medpace Popped 13% This Week ↗

October 24, 2025

The biopharmaceutical processor posted another strong earnings result for the third quarter.

Via The Motley Fool

Medpace Analysts Increase Their Forecasts After Upbeat Q3 Earnings ↗

October 24, 2025

Via Benzinga

MEDP Q3 Deep Dive: Broad-Based Growth and Strong Pipeline Fuel Upbeat Outlook

October 23, 2025

Clinical research company Medpace Holdings (NASDAQ:MEDP) reported revenue ahead of Wall Street’s expectations in Q3 CY2025, with sales up 23.7% year on year to $659.9 million. The company’s full-year...

Via StockStory

Medpace's Q3 Earnings Beat Reflects Robust Growth And Large New Wins ↗

October 23, 2025

Medpace shares climb as Q3 earnings and revenue top estimates, driven by strong bookings, rising backlog, and an upbeat 2025 guidance.

Via Benzinga

Topics Earnings

Las Vegas Sands Posts Upbeat Q3 Results, Joins Garrett Motion, LendingClub, Dow, Hexcel And Other Big Stocks Moving Higher On Thursday ↗

October 23, 2025

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

October 23, 2025

Via Benzinga

Stock Market Today: Dow Jones, Nasdaq Futures Tumble Amid US-China Trade Tensions—Tesla, IBM, American Airlines In Focus ↗

October 23, 2025

U.S. stock futures were swinging on Thursday following Wednesday’s declines. Futures of major benchmark indices were lower.

Via Benzinga

Topics Stocks

MEDPACE HOLDINGS INC (NASDAQ:MEDP) Emerges as a Top Growth and Momentum Pick ↗

October 23, 2025

MEDP Holdings stock shows strong technical and fundamental growth momentum, meeting strict trend-following criteria for a powerful setup.

Via Chartmill

Medpace Rockets On 'Another Strong Q' That Includes A Guidance Hike ↗

October 22, 2025

Medpace stock rocketed late Wednesday on "another strong Q," that included double-digit sales and profit growth.

Via Investor's Business Daily

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.